Biotie Therapies’ Options Expand On Nalmefene And Tozadenant Progress
This article was originally published in The Pink Sheet Daily
Executive Summary
Finland's only publicly listed biotech, Biotie Therapies, is reviewing its licensing and M&A options in niche CNS areas as product milestone payments and equity investments expand its cash runway.